Source: International Congress 2018 – Novel drug targets for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Suzuki (Tokyo, Japan), K. Morimoto (Tokyo, Japan), S. Yamada (Tokyo, Japan), P. Chopra (Gurgaon, India), S. Sinha (Gurgaon, India), S. Singh (Gurgaon, India), H. Kalonia (Gurgaon, India), S. Wagh (Gurgaon, India), R. Shirumalla (Gurgaon, India), M. Diwan (Gurgaon, India). Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma. 1946

Member's Comments

No comment yet.

Related content which might interest you: Profiling the impact of two JAK inhibitors in a pre-clinical model of allergic asthma Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010 Effect of SMP-028, a novel anti-inflammatory agent, on experimental allergic asthma in guinea pig model Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The effects of clinically relevant reference agents in a mouse model of severe asthma Source: International Congress 2015 – Advances in the future treatment of severe asthma Year: 2015 The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 BmTI-A, a serine protease inhibitor, reduces the chronic allergic lung inflammation in a mice model Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations Source: Eur Respir J 2016; 47: 783-791 Year: 2016 In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Roflumilast inhibits chemokine release in animal models of COPD and asthma Source: Eur Respir J 2004; 24: Suppl. 48, 690s Year: 2004 Specific NFKappaB and Rho-Quinase inhibitors compared to corticosteroid in asthma model in mice Source: International Congress 2017 – Translational studies of lung disease Year: 2017 Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003